Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$31.43 USD
-0.10 (-0.32%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $31.44 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IART 31.43 -0.10(-0.32%)
Will IART be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for IART based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IART
Inari Medical, Inc. (NARI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
IART: What are Zacks experts saying now?
Zacks Private Portfolio Services
Implied Volatility Surging for Integra (IART) Stock Options
Integra's (IART) New Site to Produce Recalled Tissue Products
Why Is Integra (IART) Up 26% Since Last Earnings Report?
Other News for IART
The 3 Best Brain-Computer Interface Stocks to Buy Now
Notable earnings before Monday's open
Integra LifeSciences Holdings Q2 2024 Earnings Preview
Alltrna Announces Updates to Its Board of Directors
Integra LifeSciences price target raised by $7 at Truist, here's why